{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:40:02Z","timestamp":1791319202567,"version":"4.3.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ahj.2024.04.009","type":"journal-article","created":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T05:31:18Z","timestamp":1713677478000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["A randomized clinical trial of catheter ablation and antiarrhythmic drug therapy for suppression of ventricular tachycardia in ischemic cardiomyopathy: The VANISH2 trial"],"prefix":"10.1016","volume":"274","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9602-2751","authenticated-orcid":false,"given":"John L.","family":"Sapp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony S.L.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratika","family":"Parkash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff S.","family":"Healey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2024.04.009_bib0001","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJM199711273372202","article-title":"A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias","volume":"337","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.04.009_bib0002","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1161\/01.CIR.101.11.1297","article-title":"Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone","volume":"101","author":"Connolly","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.04.009_bib0003","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1053\/euhj.2000.2476","article-title":"Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study","volume":"21","author":"Connolly","year":"2000","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.04.009_bib0004","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.hrthm.2017.12.026","article-title":"Defibrillator shocks and their effect on objective and subjective patient outcomes: results of the PainFree SST clinical trial","volume":"15","author":"Sears","year":"2018","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.ahj.2024.04.009_bib0005","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cjca.2022.01.016","article-title":"Ventricular tachycardia burden and mortality: association or causality?","volume":"38","author":"Samuel","year":"2022","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ahj.2024.04.009_bib0006","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jacep.2019.11.012","article-title":"Mortality risk increases with clustered ventricular arrhythmias in patients with implantable cardioverter-defibrillators","volume":"6","author":"Elsokkari","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.ahj.2024.04.009_bib0007","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.hrthm.2021.10.010","article-title":"Trends in implantable cardioverter-defibrillator programming practices and its impact on therapies: insights from a North American Remote Monitoring Registry 2007-2018","volume":"19","author":"Bennett","year":"2022","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.ahj.2024.04.009_bib0008","first-page":"e272","volume":"138","author":"Al-Khatib","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.04.009_bib0009","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.04.009_bib0010","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.hrthm.2019.03.002","article-title":"2019 HRS\/EHRA\/APHRS\/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias","volume":"17","author":"Cronin","year":"2020","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.ahj.2024.04.009_bib0011","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1513614","article-title":"Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs","volume":"375","author":"Sapp","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.04.009_bib0012","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.hrthm.2009.04.030","volume":"6","author":"Aliot","year":"2009","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.ahj.2024.04.009_bib0013","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/j.hrthm.2014.07.024","article-title":"EHRA\/HRS\/APHRS expert consensus on ventricular arrhythmias","volume":"11","author":"Pedersen","year":"2014","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.ahj.2024.04.009_bib0014","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.295.2.165","article-title":"Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial","volume":"295","author":"Connolly","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2024.04.009_bib0015","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1161\/CIRCULATIONAHA.111.072561","article-title":"Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study","volume":"124","author":"Kowey","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.04.009_bib0016","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199906173402402","article-title":"Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group","volume":"340","author":"Pacifico","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.04.009_bib0017","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/europace\/euq073","article-title":"Role of antiarrhythmic drugs in patients with implantable cardioverter defibrillators","volume":"12","author":"Van Herendael","year":"2010","journal-title":"Europace"},{"key":"10.1016\/j.ahj.2024.04.009_bib0018","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1161\/01.CIR.96.9.2823","article-title":"Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death","volume":"96","author":"Sim","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.04.009_bib0019","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.cjca.2020.04.004","article-title":"2020 Canadian Cardiovascular Society\/Canadian Heart Rhythm Society Position Statement on the Management of Ventricular Tachycardia and Fibrillation in Patients With Structural Heart Disease","volume":"36","author":"Deyell","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ahj.2024.04.009_bib0020","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1056\/NEJMoa065457","article-title":"Prophylactic catheter ablation for the prevention of defibrillator therapy","volume":"357","author":"Reddy","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.04.009_bib0021","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(09)61755-4","article-title":"Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial","volume":"375","author":"Kuck","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2024.04.009_bib0022","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1161\/CIRCULATIONAHA.122.060039","article-title":"First-line catheter ablation of monomorphic ventricular tachycardia in cardiomyopathy concurrent with defibrillator implantation: the PAUSE-SCD randomized trial","volume":"145","author":"Tung","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.04.009_bib0023","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1161\/CIRCULATIONAHA.119.043400","article-title":"Preventive or deferred ablation of ventricular tachycardia in patients with ischemic cardiomyopathy and implantable defibrillator (BERLIN VT): a multicenter randomized trial","volume":"141","author":"Willems","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.04.009_bib0024","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1161\/CIRCULATIONAHA.122.059598","article-title":"Does timing of ventricular tachycardia ablation affect prognosis in patients with an implantable cardioverter defibrillator? Results From the multicenter randomized PARTITA trial","volume":"145","author":"Della Bella","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.04.009_bib0025","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.jacc.2022.01.050","article-title":"Substrate ablation vs antiarrhythmic drug therapy for symptomatic ventricular tachycardia","volume":"79","author":"Arenal","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.04.009_bib0026","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/eurheartj\/ehac810","article-title":"Improving representativeness in trials: a call to action from the Global Cardiovascular Clinical Trialists Forum","volume":"44","author":"Filbey","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.04.009_bib0027","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1161\/01.CIR.0000145610.64014.E4","volume":"110","author":"Wathen","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.04.009_bib0028","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jacc.2006.03.037","article-title":"A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial","volume":"48","author":"Wilkoff","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.04.009_bib0029","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jacc.2008.05.011","article-title":"Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study","volume":"52","author":"Wilkoff","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.04.009_bib0030","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1093\/eurheartj\/ehp247","volume":"30","author":"Gasparini","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.04.009_bib0031","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1001\/jama.2013.4598","article-title":"Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial","volume":"309","author":"Gasparini","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2024.04.009_bib0032","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.hrthm.2016.03.022","article-title":"Extended detection time to reduce shocks is safe in secondary prevention patients: the secondary prevention substudy of PainFree SST","volume":"13","author":"Sterns","year":"2016","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.ahj.2024.04.009_bib0033","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/jce.12273","article-title":"Programming implantable cardioverter-defibrillators in patients with primary prevention indication to prolong time to first shock: results from the PROVIDE study","volume":"25","author":"Saeed","year":"2014","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.ahj.2024.04.009_bib0034","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1016\/j.hrthm.2019.02.034","article-title":"2019 HRS\/EHRA\/APHRS\/LAHRS focused update to 2015 expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing","volume":"17","author":"Stiles","year":"2020","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.ahj.2024.04.009_bib0035","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cjca.2017.08.022","article-title":"2017 comprehensive update of the Canadian cardiovascular society guidelines for the management of heart failure","volume":"33","author":"Ezekowitz","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ahj.2024.04.009_bib0036","series-title":"SF-36 health survey manual and interpretation guide","author":"Ware","year":"1993"},{"key":"10.1016\/j.ahj.2024.04.009_bib0037","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","article-title":"EuroQol: the current state of play","volume":"37","author":"Brooks","year":"1996","journal-title":"Health Policy"},{"key":"10.1016\/j.ahj.2024.04.009_bib0038","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.ahj.2024.04.009_bib0039","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1348\/135910705X52264","article-title":"Development of a measure of the concerns held by people with implanted cardioverter defibrillators: the ICDC","volume":"11","author":"Frizelle","year":"2006","journal-title":"Br J Health Psychol"},{"key":"10.1016\/j.ahj.2024.04.009_bib0040","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.116.004422","volume":"10","author":"Kuck","year":"2017","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.ahj.2024.04.009_bib0041","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1513614","article-title":"Ventricular tachycardia ablation versus escalation of antiarrhythmic drugs","volume":"375","author":"Sapp","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2024.04.009_bib0042","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1161\/CIRCULATIONAHA.113.003063","article-title":"Outcomes in catheter ablation of ventricular tachycardia in dilated nonischemic cardiomyopathy compared with ischemic cardiomyopathy: results from the Prospective Heart Centre of Leipzig VT (HELP-VT) Study","volume":"129","author":"Dinov","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.04.009_bib0043","article-title":"Long-term outcome after catheter ablation of ventricular tachycardia in patients with nonischemic dilated cardiomyopathy","volume":"9","author":"Muser","year":"2016","journal-title":"Circ Arrhythm Electrophysiol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870324000966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870324000966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T09:26:34Z","timestamp":1740821194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870324000966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":43,"alternative-id":["S0002870324000966"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2024.04.009","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized clinical trial of catheter ablation and antiarrhythmic drug therapy for suppression of ventricular tachycardia in ischemic cardiomyopathy: The VANISH2 trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2024.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}